이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Eli Lilly and Co.’s Chairman visits Samsung Bioepis and Samsung BioLogics

Collected: 2016.03.17

Distributed: 2016.03.18

Source: Go Direct

[Eli Lilly]

John Lechleiter, chairman of the U.S.-based pharmaceutical firm Eli Lilly and Co., paid a visit to South Korea’s biomedicine units Samsung Bioepis Co. and Samsung BioLogics Co. in Songdo, South Korea, underscoring international attention to the Korean bio sector after several major blockbuster breakthroughs in biomedicines.

According to sources Wednesday, Lechleiter arrived in Korea on Mar. 15 for a two-day visit. Along with the company’s local representative Paul Henry Huibers, he met Samsung Bioepis CEO Ko Han-seung and Samsung BioLogics CEO Kim Tae-han to discuss ways to broaden cooperation in biosimilars.

Headquartered in Indiana, the U.S., Eli Lilly is among the world’s top 10 pharmaceutical firms with revenue of $19.6 billion. Eli Lilly last year purchased a novel drug HM71224 developed by Hanmi Pharmaceutical Co., marking the largest $690 worth of deal sealed by Korean pharmaceutical firms. After the deal, Lechleiter also met with Hanmi Pharmaceutical Chairman Lim Sung-ki to discuss cooperation between the two companies. Following the meeting, Hanmi Pharmaceutical landed another blockbuster deal with a global pharmaceutical firm to out-license its rheumatism treatment.

Another purpose for his visit was to seek more new ventures in Korea. Eli Lilly developed the biosimilar version of Sanofi S.A.’s diabetes treatment Lantus. It agreed with Sanofi to settle a patent infringement lawsuit, and the knockoff version will go on sale in the U.S. from December this year.

By Lee Dong-in

Read in Korean

List

Previous: Hotel Shilla and Lotte Duty in a duty-free shop showdown in Tokyo

Next: S. Korea’s Dongbu Daewoo Electronics vows to up sales 200 percent in China